Patients the real drivers of the rebrand to medicine, says CMO of world's largest cannabis company

17 April 2019

Canada-based Canopy Growth (TSX: WEED) is the world’s largest cannabis company, by market cap, and it aspires to be a world leader in developing the drug as a medicine.

But the company’s chief medical officer, Mark Ware (pictured above), told The Pharma Letter that the most powerful voice in the rethink of how cannabis is being seen and used, came from patients.

“They are telling us that cannabis is helping them in a variety of forms for a bewildering array of conditions,” Dr Ware said. Of course, ever-increasing understanding of the endocannabinoid system has come alongside these patient narratives.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK